Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma

Clinical Lung Cancer

Volumn 10, Issue 4, 2009, Pages 244-248

  Wilcox, Brad E ^a   Subramaniam, Rathan M ^a   Peller, Patrick J ^a   Aughenbaugh, Gregory L ^a   Nichols III, Francis C ^a   Aubry, Marie Christine ^a   Jett, James R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Extrapleural pneumonectomy; Locoregional disease; Parietal pleurectomy; Tumor node metastasis staging

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG RESECTION; MALE; MALIGNANT MESOTHELIOMA; PATIENT SELECTION; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; SURVIVAL RATE; SURVIVAL TIME;

EID: 70349454095     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2009.n.033     Document Type: Article

References (26)

1. Price B, Ware A. Mesothelioma trends in the United States: an update based on surveillance, epidemiology and end results program data for 1973 through 2003. Am J Epidemiol 2004; 159 : 107-112.
2. Weill H, Hughes JM, Churg AM. Changing trends in US mesothelioma incidence. Occup Environ Med 2004; 61 : 438-441.
3. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353 : 1591-1603.
4. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol 1996; 14 : 1007-1017.
5. Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest 1993; 103 :373S-376S.
6. Aisner J. Current approach to malignant mesothelioma of the pleura. Chest 1995; 107 :332S-344S.
7. Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Ann Surg 1996; 224 : 288-296.
8. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117 : 54-63.
9. Yoshino I, Yamaguchi M, Okamoto T, et al. Multimodal treatment for resectable epithelial type malignant pleural mesothelioma. World J Surg Oncol 2004; 2 :11.
10. Zellos LS, Sugarbaker DJ. Multimodality treatment of diffuse malignant pleural mesothelioma. Semin Oncol 2002; 29 : 41-50.
11. Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007; 18 : 1196-1202.
12. Greene FL, Fleming ID, Fritz A, et al. AJCC Cancer Staging Manual. Page DL, ed. 6th ed. New York: Springer; 2002 :179.
13. van Ruth S, Baas P, Zoetmulder FA, et al. Surgical treatment of malignant pleural mesothelioma: a review. Chest 2003; 123 : 551-561. (Pubitemid 36269444)
14. Rusch VW, Godwin JD, Shuman WP, et al. The role of computed tomography scanning in the initial assessment and follow-up of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1988; 96 : 171-177.
15. Benard F, Sterman D, Smith RJ, et al. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 1998; 114 : 713-722.
16. Erasmus JJ, Truong MT, Smythe WR, et al. Integrated computed tomographypositron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg 2005; 129 : 1364-1370.
17. Flores RM, Akhurst T, Gonen M, et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2006; 132 : 763-768.
18. Flores RM. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer 2005; 49S1:S27-S32
19. Gerbaudo VH, Sugarbaker DJ, Britz-Cunningham S, et al. Assessment of malignant pleural mesothelioma with 18F-FDG dual head gamma-camera coincidence imaging: comparison with histopathology. J Nucl Med 2002; 43 : 1144-1149.
20. Truong MT, Marom EM, Erasmus JJ. Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging. J Thorac Imaging 2006; 21 : 146-153.
21. Schneider DB, Clary-Macy C, Challa S, et al. Positron emission tomography with F18-Flourodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2000; 120 : 128-133.
22. Flores RM, Akhurst T, Gonen M, et al. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Surg 2003; 126 : 11-16.
23. Otsuka H, Terazawa K, Otomi Y et al. Is FDG-PET/CT useful for managing malignant pleural mesothelioma? J Med Invest 2009; 56 : 16-20.
24. Plathow C, Staab A, Schmaehl A, et al. Computed tomography, positron emission tomography. Positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma. Invest Radiol 2008; 43 : 737-747.
25. Treasure T, Utley M. Mesothelioma: benefit from surgical resection is questionable. J Thorac Oncol 2007; 2 : 885-886.
26. Patz EF Jr, Shaffer K, Piwnica-Worms DR, et al. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. AJR Am J Roentgenol 1992; 152 : 961-966.